Taiwan FDA clears GenomeFrontier’s IND application for GF-CART01, a CD20/CD19 dual targeting CAR T cell therapy for hematological B cell malignancies!2025-02-11Our COO/CSO, Karen Wen was invited at Taiwan HSCT & Cell Therapy Congress 2024 in NTUH, Taiwan (July 13, 2024)2024-07-16 Our Founder/CEO/CSO, Sareina Wu, and our Director of Scientific communication, Marcus J. Calkins, will present our work as invited expert speakers at the 9th Annual CAR-TCR Summit in Boston, US. (September 17-20, 2024) For more information: https://car-tcr-summit.com/ Share0
